What is ADMA Biologics's SG&A?

ADMA Biologics (ADMA) reported SG&A of $26.74M in Q1 2026.

How has ADMA Biologics's SG&A changed year-over-year?

ADMA Biologics's SG&A increased by 11.1% year-over-year, from $24.08M to $26.74M.

What is the long-term trend for ADMA Biologics's SG&A?

Over 4 years (2021 to 2025), ADMA Biologics's SG&A has grown at a 20.9% compound annual growth rate (CAGR), from $42.9M to $91.58M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

ADMA Biologics ADMA SG&A

SG&A at other companies

AbCellera Biologics Inc.ABCL

$12.33M-35.3%

Bio-Rad LaboratoriesBIO

$212.4M+1.7%

Quest DiagnosticsDGX

$504M+5.9%

AbbVieABBV

$3.58B+8.7%

AmgenAMGN

$1.6B-5.0%

TG TherapeuticsTGTX

$88.22M+75.3%

Other financials

Income statement

See full

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

See full

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

See full

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation

See full

Market cap$2.01B-54.5%

Enterprise value$2.08B-52.5%

P/E12.2×-9.2×

P/S4×-5.7×

Profitability

See full

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

See full

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ADMA Biologics's SG&A?: ADMA Biologics (ADMA) reported SG&A of $26.74M in Q1 2026.
How has ADMA Biologics's SG&A changed year-over-year?: ADMA Biologics's SG&A increased by 11.1% year-over-year, from $24.08M to $26.74M.
What is the long-term trend for ADMA Biologics's SG&A?: Over 4 years (2021 to 2025), ADMA Biologics's SG&A has grown at a 20.9% compound annual growth rate (CAGR), from $42.9M to $91.58M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.